SA516370641B1 - مركبات حلقية غير متجانسة وطرق لاستخدامها - Google Patents
مركبات حلقية غير متجانسة وطرق لاستخدامهاInfo
- Publication number
- SA516370641B1 SA516370641B1 SA516370641A SA516370641A SA516370641B1 SA 516370641 B1 SA516370641 B1 SA 516370641B1 SA 516370641 A SA516370641 A SA 516370641A SA 516370641 A SA516370641 A SA 516370641A SA 516370641 B1 SA516370641 B1 SA 516370641B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- methods
- heterocyclic compounds
- compounds
- conjunction
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير هذا الكشف لمركبات وطرق لاستخدام تلك المركبات لعلاج اضطرابات أيضية metabolic disorders واضطرابات فرط التكاثر hyperproliferative disorders، تتضمن إعطاء المركبات مع مضادات مستقبل هرمون hormone receptor antagonists.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2816MU2013 | 2013-08-28 | ||
IN3497MU2013 | 2013-11-04 | ||
PCT/US2014/053215 WO2015031650A1 (en) | 2013-08-28 | 2014-08-28 | Heterocyclic compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SA516370641B1 true SA516370641B1 (ar) | 2018-05-21 |
Family
ID=52584081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA516370641A SA516370641B1 (ar) | 2013-08-28 | 2016-02-28 | مركبات حلقية غير متجانسة وطرق لاستخدامها |
Country Status (28)
Country | Link |
---|---|
US (1) | US9670172B2 (ar) |
EP (1) | EP3038622B1 (ar) |
JP (2) | JP2017506618A (ar) |
KR (1) | KR20160067841A (ar) |
CN (1) | CN106029072A (ar) |
AU (1) | AU2014312245B2 (ar) |
CA (1) | CA2922346A1 (ar) |
CR (1) | CR20160136A (ar) |
DK (1) | DK3038622T3 (ar) |
EC (1) | ECSP16012582A (ar) |
ES (1) | ES2676585T3 (ar) |
HR (1) | HRP20181017T1 (ar) |
HU (1) | HUE039624T2 (ar) |
IL (1) | IL244268A0 (ar) |
LT (1) | LT3038622T (ar) |
MX (1) | MX2016002443A (ar) |
NO (1) | NO20160470A1 (ar) |
PH (1) | PH12016500382A1 (ar) |
PL (1) | PL3038622T3 (ar) |
PT (1) | PT3038622T (ar) |
RS (1) | RS57338B1 (ar) |
RU (1) | RU2016111138A (ar) |
SA (1) | SA516370641B1 (ar) |
SG (2) | SG11201601486TA (ar) |
SI (1) | SI3038622T1 (ar) |
TR (1) | TR201809185T4 (ar) |
UA (1) | UA116675C2 (ar) |
WO (1) | WO2015031650A1 (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016073826A1 (en) | 2014-11-07 | 2016-05-12 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
WO2016105491A1 (en) | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
US10183015B2 (en) | 2015-03-04 | 2019-01-22 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
JP2018507235A (ja) | 2015-03-04 | 2018-03-15 | メディベイション テクノロジーズ エルエルシー | ステロール調節エレメント結合タンパク質(srebp)阻害剤 |
CN105732355A (zh) * | 2016-04-07 | 2016-07-06 | 戊言医药科技(上海)有限公司 | 1-(5-氟-2-碘苯基)乙酮的制备方法 |
MX2018013221A (es) | 2016-04-29 | 2019-06-24 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades. |
CN110072861B (zh) * | 2016-09-07 | 2022-11-11 | Fgh生物科技公司 | 用于治疗疾病的二取代吡唑类化合物 |
EP3676264A1 (en) * | 2017-08-28 | 2020-07-08 | Acurastem Inc. | Pikfyve kinase inhibitors |
MX2020007956A (es) * | 2018-01-29 | 2021-01-08 | Capulus Therapeutics Llc | Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. |
WO2020132700A1 (en) | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
WO2021154735A1 (en) * | 2020-01-27 | 2021-08-05 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
CN116041277A (zh) * | 2023-01-18 | 2023-05-02 | 中国药科大学 | 苯基和联苯基取代的五元杂环类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3796764B2 (ja) * | 1995-01-25 | 2006-07-12 | コニカミノルタホールディングス株式会社 | 金属錯体化合物及び該化合物を用いた光記録媒体 |
AU765072B2 (en) * | 1998-02-09 | 2003-09-11 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors |
US6291514B1 (en) | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
WO1999064389A1 (en) * | 1998-06-09 | 1999-12-16 | Alexandros Makriyannis | Inhibitors of the anandamide transporter as analgesic agents |
CZ20022100A3 (cs) * | 1999-12-16 | 2002-09-11 | Schering Corporation | Substituované imidazolové deriváty a farmaceutický prostředek |
TWI275589B (en) | 2000-06-22 | 2007-03-11 | Dow Agrosciences Llc | 2-(3,5-disubstituted-4-pyridyl)-4-(thienyl, thiazolyl or arylphenyl)-1,3-oxazoline compounds |
JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
EP1922068A4 (en) | 2005-08-16 | 2010-08-11 | Icagen Inc | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS |
US8229106B2 (en) | 2007-01-22 | 2012-07-24 | D.S.P. Group, Ltd. | Apparatus and methods for enhancement of speech |
AU2008214095B2 (en) | 2007-02-02 | 2014-07-10 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9212179B2 (en) | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
CA2748274A1 (en) * | 2008-12-30 | 2010-07-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
CA2786424A1 (en) | 2010-01-08 | 2011-07-14 | Ruga Corporation | Raf kinase inhibitors |
WO2012084678A1 (en) | 2010-12-23 | 2012-06-28 | Syngenta Participations Ag | Novel imidazoles useful as plant fungicides |
GB201116017D0 (en) | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
WO2013096642A1 (en) | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
BR112015032540A2 (pt) | 2013-06-26 | 2017-07-25 | Baylor College Medicine | síndrome de rett e tratamentos para a mesma |
-
2014
- 2014-08-28 SG SG11201601486TA patent/SG11201601486TA/en unknown
- 2014-08-28 SI SI201430774T patent/SI3038622T1/en unknown
- 2014-08-28 MX MX2016002443A patent/MX2016002443A/es unknown
- 2014-08-28 CR CR20160136A patent/CR20160136A/es unknown
- 2014-08-28 CN CN201480054063.3A patent/CN106029072A/zh active Pending
- 2014-08-28 RS RS20180723A patent/RS57338B1/sr unknown
- 2014-08-28 TR TR2018/09185T patent/TR201809185T4/tr unknown
- 2014-08-28 RU RU2016111138A patent/RU2016111138A/ru not_active Application Discontinuation
- 2014-08-28 ES ES14839213.7T patent/ES2676585T3/es active Active
- 2014-08-28 PT PT148392137T patent/PT3038622T/pt unknown
- 2014-08-28 WO PCT/US2014/053215 patent/WO2015031650A1/en active Application Filing
- 2014-08-28 JP JP2016537857A patent/JP2017506618A/ja active Pending
- 2014-08-28 AU AU2014312245A patent/AU2014312245B2/en not_active Ceased
- 2014-08-28 KR KR1020167007463A patent/KR20160067841A/ko not_active Application Discontinuation
- 2014-08-28 LT LTEP14839213.7T patent/LT3038622T/lt unknown
- 2014-08-28 HU HUE14839213A patent/HUE039624T2/hu unknown
- 2014-08-28 UA UAA201603203A patent/UA116675C2/uk unknown
- 2014-08-28 SG SG10201806370QA patent/SG10201806370QA/en unknown
- 2014-08-28 PL PL14839213T patent/PL3038622T3/pl unknown
- 2014-08-28 DK DK14839213.7T patent/DK3038622T3/en active
- 2014-08-28 EP EP14839213.7A patent/EP3038622B1/en active Active
- 2014-08-28 CA CA2922346A patent/CA2922346A1/en not_active Abandoned
- 2014-08-28 US US14/471,977 patent/US9670172B2/en not_active Expired - Fee Related
-
2016
- 2016-02-24 IL IL244268A patent/IL244268A0/en unknown
- 2016-02-26 PH PH12016500382A patent/PH12016500382A1/en unknown
- 2016-02-28 SA SA516370641A patent/SA516370641B1/ar unknown
- 2016-03-18 NO NO20160470A patent/NO20160470A1/en not_active Application Discontinuation
- 2016-03-24 EC ECIEPI201612582A patent/ECSP16012582A/es unknown
-
2018
- 2018-07-02 HR HRP20181017TT patent/HRP20181017T1/hr unknown
-
2019
- 2019-03-20 JP JP2019052536A patent/JP2019089854A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA516370641B1 (ar) | مركبات حلقية غير متجانسة وطرق لاستخدامها | |
MX2016005560A (es) | Compuestos agonistas triples de glucagon-glp-1-gip. | |
MX2020014300A (es) | Compuestos heterociclicos utiles en el tratamiento de enfermedades. | |
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
HK1226084A1 (zh) | 用於治療糖尿病的gip和glp-1受體雙重激動劑 | |
PH12020500255A1 (en) | Use of nk-1 receptor antagonist serlopitant in pruritus | |
MX2016005556A (es) | Compuestos agonistas duales de gip-glp-1 y procedimientos. | |
PH12017500164A1 (en) | Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
MX2015009106A (es) | Composiciones de solución sólida y su uso en el tratamiento del dolor intenso. | |
IL239927A0 (en) | kv1.3 antagonists and methods of use | |
HK1220386A1 (zh) | 受體拮抗劑在軟骨疾病的治療中的用途 | |
HK1224179A1 (zh) | 針對成纖維細胞生長因子受體- 的化合物和治療方法 | |
MY175326A (en) | Product and method for treating diarrhea | |
MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
IL242748B (en) | Nmdar agonists for use in the treatment of autoimmune-induced glutamatergic receptor dysfunction | |
MX2016011706A (es) | Formulaciones de progesterona. | |
MX2017012449A (es) | Tratamiento del dolor. | |
MA40553A (fr) | Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes | |
UA89943U (uk) | Спосіб прискорення провідності нервово-м'язового імпульсу в спортсменів | |
UA89713U (ru) | Способ ранней реабилитации детей после перенесенной внегоспитальной пневмонии | |
UA91089U (uk) | Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті |